Aurobindo Pharma's AuroPeptides Facility Gets 1 USFDA Observation
Hyderabad: The United States Food and Drug Administration (USFDA) has concluded a routine inspection at AuroPeptides Ltd, a manufacturer of Peptide APIs and a subsidiary/business arm of Aurobindo Pharma Limited, with only one observation related to facility and equipment maintenance.
The observation does not pertain to data integrity or related Good Manufacturing Practices (GMP) compliance.
Aurobindo Pharma Limited disclosed the development pursuant to Regulation 30 of the Securities and Exchange Board of India (SEBI) (Listing Obligations & Disclosure Requirements) Regulations, 2015, in a communication dated August 21, 2026, addressed to the Listing Department of the National Stock Exchange of India Limited and the Corporate Relations Department of BSE Limited.
The US FDA conducted the routine inspection at AuroPeptides Ltd, located at Indrakaran Village, Kandi Mandal, Sangareddy District, Telangana – 502329. The inspection was carried out from August 17 to August 21, 2026. AuroPeptides is identified in the disclosure as a manufacturer of Peptide APIs.
According to the company, the inspection concluded with only one observation, which concerned facility and equipment maintenance. Aurobindo Pharma specifically stated that the observation was not related to data integrity or related GMP compliance. Corrective action had already been initiated during the course of the inspection, while the company's formal response is to be submitted within the stipulated timeline.
The company stated that the inspection outcome reaffirms its continued commitment to maintaining robust quality and compliance standards across its manufacturing facilities. It further said that the Stock Exchanges will be kept informed about any further developments in this regard, as required under the applicable regulations.
Also Read: Aurobindo Pharma Inks Voluntary Licensing Pact with MSD for HIV Prevention Medicine
